Effectiveness outcomes.

Effectiveness outcomes.</p

Patients flow diagram.

CAR, chimeric antigen receptor; DP, disease progression; ICANS, immune effector cell-associated neurotoxicity syndrome; CR, complete response; PR, partial response; HLH, Hemophagocytic lymphohistiocytosis. (PDF)</p

Costing by activity.

Costing by activity.</p

Costing by stage.

Costing by stage.</p

Baseline patient characteristics ^a.

Baseline patient characteristics a.</p

Progression-free survival curve for all patients (n = 20).

Median PFS (months): 7.3 (95%CI: 5.3 to not reached).</p

Safety: Toxicity events, grade and treatment.

Safety: Toxicity events, grade and treatment.</p

Healthcare resources utilization.

Healthcare resources utilization.</p

Overall survival curve for all patients (n = 20).

Median OS (months): 9.2 (95%CI: 6.3 to not reached).</p